ClinicalTrials.gg
CompletedNCT03659552Updated Sep 6, 2018

Percutaneous Temporary Placement of a Transvenous Phrenic Nerve Stimulator for Diaphragm Pacing Using Jugular Access

An interventional study of LIVE Catheter in Ventilator-Induced Lung Injury, sponsored by Lungpacer Medical Inc.. Completed at 1 site in Paraguay. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-06.

Sponsored by Lungpacer Medical Inc. · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Study conducted to confirm phrenic nerve stimulation using the a transvenous Phrenic Nerve Stimulator in the left jugular vein.

Read the detailed description

The Lungpacer Jugular Access Feasibility System is a prototype for the Lungpacer Diaphragm Pacing Therapy System (DPTS) and consists of the LIVE Catheter, a stimulation system with a Multipole Panel Accessory, an airflow sensor and a Heart Rate Data Capture Device. The catheter is intended for inclusion in the commercial product. The stimulation system with a Multipole Panel Accessory and a Heart Rate Data Capture Device is an interim component created to enable initial safety and feasibility testing of the Lungpacer DPTS concept.

02

Conditions studied

  • Ventilator-Induced Lung Injury
03

In context

Ventilator-Induced Lung Injury

122 studies on the registry are indexed under Ventilator-Induced Lung Injury; 40 are open to participants now.

This study's enrollment of 13 is below the median of 40 across 76 interventional studies indexed under Ventilator-Induced Lung Injury.

Browse Ventilator-Induced Lung Injury studies →

Lead sponsor

Lungpacer Medical Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older;
  • Able and willing to give or whose legally authorized representative is able and willing to give informed consent;
  • Able to undergo general anesthesia (sedation, intubation, and mechanical ventilation);
  • Acceptable indication for atrial septal defect closure.

Exclusion criteria

Exclusion Criteria:

  • Subject has an of \< 30%
  • Subject has a co-morbid illness or \< 2 years
  • Subject has experienced an acute myocardial infarction within 72 hours prior to this procedure
  • Subject is for or unwilling to take aspirin or anticoagulants
  • Subject is in cardiogenic shock
  • Subject has other cardiovascular disease requiring open heart surgery
  • Subject is known to have a demonstrated intra cardiac thrombus on echocardiography
  • Subject has been treated with paralytic medications within 72 hours prior to procedure
  • Subject has significant thoracic abnormalities such that placement of a left subclavian line would be difficult
  • Inability to cannulate the left subclavian vein (post-consent exclusion)
  • Subject has a known or suspected phrenic nerve paralysis
  • Subject has co-existing temporary or implanted cardiac electrical devices such as a pacemaker or defibrillator
  • Subject has an active systemic infection or local infection at or around the insertion site
  • Subject is known or suspected to be pregnant or is lactating
  • Subject will be unavailable for, or is unwilling to comply with, follow up requirements of the protocol
  • Subject is currently enrolled in any other study of an drug or device who has received treatment under that protocol with the investigational product during the 30 days prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Temporary diaphragmatic pacing

    There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left jugular vein.

    Device: LIVE Catheter

Interventions

  • DeviceLIVE Catheter

    Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.

06

What researchers measure

Primary outcomes

  1. Successful insertion of the LIVE Catheter into the left jugular vein and stimulation of phrenic nerves

    To determine whether in an anesthetized (sedated, intubated, and mechanically ventilated) patient the LIVE Catheter can be inserted percutaneously in the left jugular vein and, via the electrical stimulator, to transvenously stimulate one or both phrenic nerves causing the diaphragm to contract

    Time frame: through study completion, an average of 14 days

Secondary outcomes

  1. Absence of device related or procedure related adverse events

    Assess subject for adverse events status up to 48 hours post procedure

    Time frame: through study completion, an average of 14 days

Other outcomes

  1. Tidal volume assessement

    Generation of tidal volume upon delivery of stimulation to the phrenic nerve(s) without spontaneous or ventilator support, as measured by the ventilator

    Time frame: during the procedure only up to 3 hours

07

Study locations

1 site
  • Italian Hospital
    Asunción, Casa Zanotti, Paraguay
08

References and documents

Publications

  • Michalek P, Kautznerova D. Combined use of ultrasonography and neurostimulation for therapeutic phrenic nerve block. Reg Anesth Pain Med. 2002 May-Jun;27(3):306-8. No abstract available. PubMed 12016605 ↗
  • Escher DJ, Furman S, Solomon N, Schwedel JB. Transvenous pacing of the phrenic nerves. Am Heart J. 1966 Aug;72(2):283-4. doi: 10.1016/0002-8703(66)90456-x. No abstract available. PubMed 5915563 ↗
  • Escher DJ, Ashley W, Ertag W, Parker B, Furman S, Robinson G. Clinical control of respiration by transvenous phrenic pacing. Trans Am Soc Artif Intern Organs. 1968;14:192-7. No abstract available. PubMed 4882945 ↗
  • Eisele JH, Noble MI, Katz J, Fung DL, Hickey RF. Bilateral phrenic-nerve block in man: technical problems and respiratory effects. Anesthesiology. 1972 Jul;37(1):64-9. doi: 10.1097/00000542-197207000-00012. No abstract available. PubMed 5050104 ↗
  • Aubier M, Murciano D, Lecocguic Y, Viires N, Jacquens Y, Squara P, Pariente R. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. N Engl J Med. 1985 Aug 15;313(7):420-4. doi: 10.1056/NEJM198508153130705. PubMed 3860734 ↗
  • Ishii K, Kurosawa H, Koyanagi H, Nakano K, Sakakibara N, Sato I, Noshiro M, Ohsawa M. Effects of bilateral transvenous diaphragm pacing on hemodynamic function in patients after cardiac operations. Experimental and clinical study. J Thorac Cardiovasc Surg. 1990 Jul;100(1):108-14. PubMed 2366549 ↗
  • Allen GM, McKenzie DK, Gandevia SC, Bass S. Reduced voluntary drive to breathe in asthmatic subjects. Respir Physiol. 1993 Jul;93(1):29-40. doi: 10.1016/0034-5687(93)90065-i. PubMed 8367614 ↗
  • Mulvey DA, Aquilina RJ, Elliott MW, Moxham J, Green M. Diaphragmatic dysfunction in neuralgic amyotrophy: an electrophysiologic evaluation of 16 patients presenting with dyspnea. Am Rev Respir Dis. 1993 Jan;147(1):66-71. doi: 10.1164/ajrccm/147.1.66. PubMed 8420434 ↗
  • McKenzie DK, Allen GM, Gandevia SC. Reduced voluntary drive to the human diaphragm at low lung volumes. Respir Physiol. 1996 Aug;105(1-2):69-76. doi: 10.1016/0034-5687(96)00021-7. PubMed 8897652 ↗
  • Oo T, Watt JW, Soni BM, Sett PK. Delayed diaphragm recovery in 12 patients after high cervical spinal cord injury. A retrospective review of the diaphragm status of 107 patients ventilated after acute spinal cord injury. Spinal Cord. 1999 Feb;37(2):117-22. doi: 10.1038/sj.sc.3100775. PubMed 10065750 ↗
  • Ahn B, Beaver T, Martin T, Hess P, Brumback BA, Ahmed S, Smith BK, Leeuwenburgh C, Martin AD, Ferreira LF. Phrenic nerve stimulation increases human diaphragm fiber force after cardiothoracic surgery. Am J Respir Crit Care Med. 2014 Oct 1;190(7):837-9. doi: 10.1164/rccm.201405-0993LE. No abstract available. PubMed 25271750 ↗
  • Germany R, Joseph S, James K, Kao A. A novel therapeutic approach for the treatment of central sleep apnea: The remede(R) system. Cardiovasc Revasc Med. 2014 Jun;15(4):235-9. doi: 10.1016/j.carrev.2014.03.007. Epub 2014 Mar 21. PubMed 24726495 ↗
  • Linhart M, Nielson A, Andrie RP, Mittmann-Braun EL, Stockigt F, Kreuz J, Nickenig G, Schrickel JW, Lickfett LM. Fluoroscopy of spontaneous breathing is more sensitive than phrenic nerve stimulation for detection of right phrenic nerve injury during cryoballoon ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2014 Aug;25(8):859-865. doi: 10.1111/jce.12431. Epub 2014 May 18. PubMed 24724724 ↗

Individual participant data

Plan to share: No — Lungpacer may at any time publish the results of and information pertaining to the investigation subject only to compliance with regulatory requirements pertaining to patient protected health information

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Jun 2018, 1 month.

Of 40 interventional studies with no phase under Ventilator-Induced Lung Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 53. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2018
First posted
Sep 6, 2018
StartActual
May 7, 2018
Primary completionActual
Jun 30, 2018
CompletionActual
Aug 30, 2018
Last update
Sep 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03659552
Lead sponsor
Lungpacer Medical Inc.
Responsible party
Sponsor
First posted
Sep 6, 2018
Start date
May 7, 2018
Primary completion
Jun 30, 2018
Completion
Aug 30, 2018
Last update
Sep 6, 2018

Study contacts

Linda Clark, RN
study director · Lungpacer Medical Inc.
Adrian Ebner, MD
principal investigator · Italian Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion